10.1016/j.intimp.2022.108717 Int Immunopharmacol
Postmenopausal women experience a two- to three-fold increase in cardiometabolic risk, underscoring the need for targeted interventions. (Mauvais-Jarvis et al., 2017) Not All GLP-1 Agonists Are the Same Todays GLP-1 therapies vary in structure, receptor affinity, and clinical profile, and these nuances may matter for midlife women: Exenatide (Byetta, Bydureon): Derived from Gila monster venom peptide
Your ideal target depends on your age, weight, activity level, and overall health, so the best number is the one your provider sets with you
They can advise on which drug may work best for you and not interact with other meds youre taking
To explore real skin booster before and after results, see our dedicated White Booster+ guide
37 , 10601074 e1064 (2025)